Unity Biotechnology, Inc. Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost
Unity Biotechnology, Inc. had Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost of $4.51 million as of 2024-12-31, per its 10-K filed 2025-03-07.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross › Deferred Tax Assets, Tax Deferred Expense
us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost · last filed 2025-03-07
- 2024-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $4.51M.
- 2023-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $5.08M.
- 2022-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $4.59M.
- 2021-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $5.23M.
| Period end | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost |
|---|---|
| 2024-12-31 | $4.51M 10-K · filed 2025-03-07 |
| 2023-12-31 | $5.08M 10-K · filed 2025-03-07 |
| 2022-12-31 | $4.59M 10-K · filed 2024-04-15 |
| 2021-12-31 | $5.23M 10-K · filed 2023-03-15 |
| 2020-12-31 | $4.33M 10-K · filed 2022-03-15 |
| 2019-12-31 | $3.51M 10-K · filed 2021-03-23 |
| 2018-12-31 | $1.84M 10-K · filed 2020-03-11 |
| 2017-12-31 | $671.00K 10-K · filed 2019-03-06 |